Patients with hepatitis C virus (HCV) taking direct-acting antiviral (DAA) treatments, who have been treated for hepatocellular carcinoma (HCC), had a high rate of cancer recurrence, according to a new study presented at the annual International Liver Congress in Barcelona, Spain (abstract LBP506).
“Even in a relatively short observation period, we have